Elevance Health (ELV) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Elevance Health (ELV) closed at $476.96, marking a -0.28% move from the previous day. This change lagged the S&P 500’s daily gain of 0.8%. Meanwhile, the Dow experienced a rise of 0.18%, and the technology-dominated Nasdaq saw an increase of 1.37%.
The health insurer’s stock has climbed by 5.54% in the past month, exceeding the Medical sector’s gain of 2.68% and the S&P 500’s gain of 4.39%.
The investment community will be paying close attention to the earnings performance of Elevance Health in its upcoming release. The company is predicted to post an EPS of $5.60, indicating a 7.07% growth compared to the equivalent quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $41.97 billion, showing a 5.8% escalation compared to the year-ago quarter.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $33.04 per share and a revenue of $169.83 billion, indicating changes of +13.66% and +9.1%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Elevance Health. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts’ confidence in the company’s business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there’s been a 0.01% fall in the Zacks Consensus EPS estimate. As of now, Elevance Health holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Elevance Health has a Forward P/E ratio of 14.48 right now. This signifies a discount in comparison to the average Forward P/E of 20.55 for its industry.
We can additionally observe that ELV currently boasts a PEG ratio of 1.2. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company’s expected earnings growth trajectory. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.66.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 35% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Only $1 to See All Zacks’ Buys and Sells
We’re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not – they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services likeSurprise Trader, Stocks Under $10, Technology Innovators,and more. They’ve already closed 162 positions with double- and triple-digit gains in 2023 alone.
Elevance Health, Inc. (ELV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Original: Investing Feed: Elevance Health (ELV) Stock Slides as Market Rises: Facts to Know Before You Trade